Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778188 | 0.87 | KDM4E (0.59) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL569249 | 0.87 | ALDH1A1 (0.59) | ALDH1A1KDM4ECA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL29890892 | 0.85 | ALDH1A1 (0.57) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL14479830 | 0.81 | KDM4E (0.53) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL29371765 | 0.81 | KDM4E (0.53) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL2532558 | 0.81 | CA12 (0.50) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL31368540 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL1179017 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL21200349 | 0.80 | KDM4E (0.52) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL1291158 | 0.80 | KDM4E (0.52) | ALDH1A1KDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-107531698-B | Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| CN-105980378-A | Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B | 爱尔兰詹森科学公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2016148306-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016148306-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-22 | — | — | WO | disclosed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015118057-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | WO | disclosed |
| EP-2881394-A1 | CONDENSED RING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| CN-104619707-A | Condensed ring heterocyclic compound | KYOWA HAKKO KIRIN CO LTD | 2015-05-13 | — | — | CN | disclosed |
| WO-2011159864-A1 | JTE013 ANALOGS AND METHODS OF MAKING AND USING SAME | BRACCO IMAGING S.P.A. (IT) | 2011-12-22 | — | — | WO | disclosed |
| WO-2008015196-A1 | 5-,7-BIS-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES | NYCOMED GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | ALDH1A1 1847/4885KDM4E 4286/4885CA12 4260/4885 |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | ALDH1A1 646/4885KDM4E 3981/4885CA12 272/4885 |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | ALDH1A1 3820/4885KDM4E 800/4885CA12 4580/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | ALDH1A1 1900/4885KDM4E 814/4885CA12 4753/4885 |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | TRPV1, TRPV2, TRPV3 | ALDH1A1 4202/4885KDM4E 3471/4885CA12 2480/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | ALDH1A1 1682/4885KDM4E 4387/4885CA12 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.